Patents by Inventor Nigel James Parr

Nigel James Parr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 10946025
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 16, 2021
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • NOVEL COMPOUNDS
    Publication number: 20200206237
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Compounds
    Patent number: 10624898
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: April 21, 2020
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • NOVEL COMPOUNDS
    Publication number: 20190328744
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Compounds
    Patent number: 10383879
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 20, 2019
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • NOVEL COMPOUNDS
    Publication number: 20190175608
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 20, 2019
    Publication date: June 13, 2019
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • NOVEL COMPOUNDS
    Publication number: 20180325911
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: May 16, 2018
    Publication date: November 15, 2018
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • NOVEL COMPOUNDS
    Publication number: 20170157136
    Abstract: The invention is directed to methods of treatment using compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • NOVEL COMPOUNDS
    Publication number: 20170015656
    Abstract: The invention is directed to certain novel compounds. Specifically, crystalline forms of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide and crystalline 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole, along with salts thereof.
    Type: Application
    Filed: August 2, 2016
    Publication date: January 19, 2017
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Novel Polymorphs and Salts
    Publication number: 20160237073
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR, Robert David WILLACY
  • Polymorphs and salts
    Patent number: 9353098
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 31, 2016
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Indazole derivatives for use in the treatment of influenza virus infection
    Patent number: 9326987
    Abstract: The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: May 3, 2016
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Novel Compounds
    Publication number: 20150328226
    Abstract: The invention provides a combination comprising compounds of formula (I) or salts thereof, and one or more therapeutic agents.
    Type: Application
    Filed: May 27, 2015
    Publication date: November 19, 2015
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Novel Polymorphs and Salts
    Publication number: 20150299177
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: June 29, 2015
    Publication date: October 22, 2015
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR, Robert David WILLACY
  • Polymorphs and salts
    Patent number: 9102668
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: August 11, 2015
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • 6-(1-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof
    Patent number: 8993576
    Abstract: The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: March 31, 2015
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr, Robert David Willacy
  • Novel Polymorphs and Salts
    Publication number: 20140256721
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: April 14, 2014
    Publication date: September 11, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Compounds
    Patent number: 8765743
    Abstract: The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 1, 2014
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Polymorphs and salts
    Patent number: 8735390
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: May 27, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Novel Compounds
    Publication number: 20140080830
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): And salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr